ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Carb-X funds Procarta’s oligonucleotide-based antibacterials

by Lisa M. Jarvis
September 21, 2019 | APPEARED IN VOLUME 97, ISSUE 37

 

Stevenage, England-based Procarta Biosystems will receive up to $9.2 million in funding from Carb-X, a public-private partnership that backs development of antibiotics, vaccines, and diagnostics for drug-resistant bacteria. Procarta is developing oligonucleotide antimicrobials against gram-negative pathogens. It uses nanoparticles to deliver oligonucleotides to cells, where they target bacterial transcription factors and thus block bacterial gene expression.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment